Efficacy and acceptability of the new oral phosphate binderLenziaren®in healthy cats fed a renal diet
Authors:
Open Access
- 3 November 2014
- journal article
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 38 (3) , 278-289
Abstract
The efficacy and acceptability of the new oral phosphate binder Lenziaren®(SBR759) were evaluated in healthy cats fed with a commercial diet containing low amounts of phosphate (‘renal diet’). Lenziaren®at 0.125, 0.25, 0.5 and 1 g/day was compared to a reference product Lantharenol®(3.0 g/day) and a placebo in a masked, randomized, parallel‐group design study in 36 cats (n = 6 per group). All products were mixed with the ration which was fed once daily for 28 days. Lenziaren®produced significant dose‐related reductions in serum and urine phosphate concentrations, faecal apparent phosphorus digestibility and fractional urinary phosphate excretion. Cats administered Lenziaren®consumed significantly less food than the placebo group, but this had no negative impact on body weight or acceptability assessments. When compared to the positive control, Lantharenol®, Lenziaren®was significantly more acceptable (0.125, 0.5 and 1.0 g/day doses), was associated with higher food consumption (0.125, 0.5 and 1.0 g/day doses) and had greater efficacy in reducing serum phosphate (0.5 and 1.0 g/day) and urine phosphate concentrations (1.0 g/day). In conclusion, Lenziaren®was an effective oral phosphate binder in healthy cats fed with a renal diet. Lenziaren®was well accepted and tolerated. Dosages of 0.25–1.0 g/cat per day are recommended for clinical testing.Keywords
Funding Information
- Novartis Animal Health Inc (None)
This publication has 18 references indexed in Scilit:
- Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in catsBMC Veterinary Research, 2012
- Efficacy and safety of SBR759, a novel calcium‐free, iron(III)‐based phosphate binder, in Asian patients undergoing hemodialysis: A 12‐week, randomized, open‐label, dose‐titration study versus sevelamer hydrochlorideNephrology, 2011
- PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney diseaseClinical Nephrology, 2010
- Efficacy and safety of SBR759, a new iron-based phosphate binderKidney International, 2010
- Treatment Options for Hyperphosphatemia in Feline CKD: What's Out there?Journal of Feline Medicine and Surgery, 2009
- Survival in Cats with Naturally Occurring Chronic Kidney Disease (2000–2002)Journal of Veterinary Internal Medicine, 2008
- Prognostic Factors in Cats with Chronic Kidney DiseaseJournal of Veterinary Internal Medicine, 2007
- Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in catsJournal of the American Veterinary Medical Association, 2006
- Bone metabolism and disease in chronic kidney diseaseAmerican Journal of Kidney Diseases, 2003
- Phosphate binders on iron basis: A new perspective?Kidney International, 1999